Two monoclonal antibodies, NCC-LU-35 and NCC-LU-81, have been established after immunization of mice with membrane preparations of human lung cancer Lu65 tumor xenograft cells grown in vivo and intact cells cultured in vitro, respectively. These two antibodies react specifically with a majority of human adenocarcinomas, irrespective of the host's blood group ABO status, as well as with normal tissues and erythrocytes of blood group A individuals. The antigenicity is associated with a high molecular weight mucin-like glycoprotein separated by gel filtration of Lu65 tumor extracts. The epitope of the mucin-like glycoprotein has been identified as a-N-acetylgalactosaminyl residue directly linked O-glycosidically to serine or threonine residues of polypeptides. This epitope was serologically detected several years ago and given the name Tn. Our identification of the epitope is based on the following results: (i) The antigen is sensitive to a-Nacetylgalactosaminidase, but not to sialidase or a-fucosidase.(ii) Various mono-and difucosyl A determinants, either type 1 or type 2 chain, cross-react with both antibodies. (ii) The reactivity with both antibodies can be created by treatment of glycophorin A of normal erythrocytes with sialidase followed by 13-galactosidase. Monoclonal antibodies NCC-LU-35 and NCC-LU-81 were established after immunization of mice with lung carcinoma Lu65 cells. The antigen defined by both antibodies is not expressed in various normal tissues of blood group B and 0 hosts, but it is strongly expressed in various adenocarcinomas derived from blood group B and 0 as well as A hosts.